Results 1 to 10 of about 11,568,194 (143)
Journal of the Korean Society of RadiologyThe introduction of anti-amyloid therapies for Alzheimer’s disease (AD), such as lecanemab (Lequembi ®), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI. To optimize
Jimin Kim +10 more
doaj +1 more source
Lecanemab for mild Alzheimer disease – is there a way forward?
Drugs in ContextThis Editorial reviews data on the efficacy and adverse effects of lecanemab amongst individuals with mild Alzheimer disease. Additionally, the recent controversy regarding the rejection by the EMA of a marketing authorization request for lecanemab ...
Rajesh R Tampi
doaj +1 more source
Alzheimer’s Research & Therapy, 2018 Background Anti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer’s disease (AD). However, Aβ peptide adopts multiple conformations and the pathological forms to be specifically targeted have not been identified.
Laurent Pradier +24 more
doaj +1 more source
Cerebral Amyloid Angiopathy: Clinical Presentation, Sequelae and Neuroimaging Features—An Update
BiomedicinesThe prevalence of cerebral amyloid angiopathy (CAA) has been shown to increase with age, with rates reported to be around 50–60% in individuals over 80 years old who have cognitive impairment. The disease often presents as spontaneous lobar intracerebral
Stefan Weidauer, Elke Hattingen
doaj +1 more source
Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease MonitoringINTRODUCTION Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of early symptomatic Alzheimer's disease.
Bethany C. Curd +8 more
doaj +1 more source
From Lesion to Decision: AI for ARIA Detection and Predictive Imaging in Alzheimer’s Disease
BiomedicinesBackground: Alzheimer’s disease (AD) remains the leading cause of dementia worldwide, with anti-amyloid monoclonal antibodies (MABs) marking a significant advance as the first disease-modifying therapies. Their use, however, is limited by amyloid-related
Rafail C. Christodoulou +11 more
doaj +1 more source
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Molecules, 2018 Passive immunotherapy has emerged as a very promising approach for the treatment of Alzheimer’s disease and other neurodegenerative disorders, which are characterized by the misfolding and deposition of amyloid peptides. On the basis of the amyloid
Stephan Schilling +3 more
doaj +1 more source
White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease MonitoringWhite matter hyperintensities (WMHs) are highly prevalent in Alzheimer's disease (AD) and arise from interacting vascular pathologies (including hypertensive small vessel disease and cerebral amyloid angiopathy) alongside inflammatory and ...
Antoine Garnier‐Crussard +7 more
doaj +1 more source
Journal of Education, Health and SportAlzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and neuronal damage. Anti-amyloid monoclonal antibodies such as aducanumab, lecanemab, and donanemab, represent the first disease-modifying therapies for ...
Agnieszka Skoczeń +9 more
doaj +1 more source
Lecanemab over a two-year duration: Key insights from a regional specialty medical center
The Journal of Prevention of Alzheimer's DiseaseBackground and objectives: The anti-amyloid monoclonal antibody lecanemab (Leqembi®) treats patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).
Lisa B.E. Shields +14 more
doaj +1 more source